Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma

OBJECTIVES: Previous pharmacogenetics studies showed that genetic variants could be indicative of the response to chemotherapy. We aimed to investigate whether variants of FasL, MSH2, ABCC5, CASP3 and CYP3A4 are associated with the outcome after chemotherapy-based treatment in osteosarcoma. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Leilei, Xia, Chao, Sun, Qi, Sheng, Fei, Xiong, Jin, Wang, Shoufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066469/
https://www.ncbi.nlm.nih.gov/pubmed/30065912
http://dx.doi.org/10.1016/j.jbo.2018.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066469/
https://www.ncbi.nlm.nih.gov/pubmed/30065912
http://dx.doi.org/10.1016/j.jbo.2018.04.003

Ejemplares similares